Healthcare organizations spend enormous effort evaluating products and making decisions. The bigger opportunity may be what happens after the committee says yes.
Healthcare organizations have spent years improving how they evaluate products, technologies, and services. We built committees, developed intake processes, strengthened evidence review, incorporated clinical voices, added financial analysis, established approval pathways, and created policies intended to bring greater discipline to product decisions. All those improvements matter.
Healthcare should have rigorous processes for determining what enters the organization, particularly when those decisions affect patient care, clinical workflow, cost, safety, and operational performance. But there is a problem we do not talk about nearly enough. We have become very focused on making the decision. The decision was never the outcome.
A product can pass Value Analysis and still fail to create the expected value. A sourcing initiative can receive strong clinical support and still miss its financial target. A contract can be signed and never achieve expected compliance. A conversion can be approved and then stall because inventory was not depleted, education was incomplete, locations were not converted consistently, or clinicians continued using the incumbent product. A new technology can have an impressive clinical and financial business case and still underperform because utilization never reaches the assumptions used to justify the investment.
In each of these situations, the original decision may have been completely reasonable. The problem happened afterward. That is the next frontier for Value Analysis.
The Value Realization Gap
There is a gap inside many healthcare organizations between value approved and value realized. It is easy to miss because our traditional milestones can make an initiative appear complete long before the organization has actually achieved the intended outcome.
The committee approved it. The contract was executed. The supplier was notified. The projected savings were entered into a tracker. The project moved to green. Everyone moved on to the next initiative.
But did behavior actually change? Did utilization move? Did the old product leave the organization? Did contract compliance increase? Did the expected clinical or operational improvement occur? Did the financial impact appear in actual purchasing behavior? Six months later, could someone demonstrate that the organization received the value presented in the original business case? Those are very different questions.
This is the Value Realization Gap: The distance between making a good decision and actually producing the clinical, financial, and operational outcomes that justified that decision. Closing that gap requires us to think about Value Analysis differently.
Approval Is a Milestone, Not an Outcome
Consider the lifecycle of a typical Value Analysis initiative:
Request → Evaluate → Decide → Implement → Adopt → Measure → Sustain
Healthcare has historically placed enormous energy into the first three stages.
- Was the request appropriate?
- What does the evidence show?
- Is the product clinically acceptable?
- What does it cost?
- What is the reimbursement impact?
- Are there alternatives?
- What do physicians or clinicians think?
- Should we approve it?
Those are necessary questions, but look at what happens after the decision.
- Someone must determine how the change will be implemented.
- Someone must communicate it.
- Someone must manage existing inventory.
- Someone must coordinate with the supplier.
- Someone must ensure the item master and pricing are correct.
- Someone may need to manage EDI, distribution, training, stocking locations, par levels, preference cards, procedural workflows, or other operational dependencies.
- Clinicians must know what is changing and when.
- Operations must be prepared.
- Old products may need to be depleted or removed.
- Purchasing behavior must change.
- Utilization must be monitored.
- Financial assumptions must eventually be compared with actual performance.
- And if adoption does not occur, someone must recognize it and intervene.
That is where value is either realized or lost. Yet in many organizations, the governance structure becomes less clear precisely when execution becomes most important.
Where Does Ownership Go After the Vote?
This may be one of the most important questions Value Analysis leaders can ask: Who owns the outcome after approval?
Not who owns the meeting. Not who entered the request. Not who negotiated the contract. Not who presented the business case. Who owns making sure the organization actually achieves the outcome? The answer is often surprisingly difficult.
Supply Chain may assume Operations owns implementation. Operations may assume the clinical department owns adoption. The clinical department may assume the supplier is providing education. Finance may assume Supply Chain is tracking savings. Value Analysis may consider its work complete once the committee approves the request.
Meanwhile, Procurement is still receiving orders for the incumbent product. This is how good decisions quietly lose value. Not because anyone intentionally ignored the initiative, but because responsibility became fragmented once the decision moved from evaluation into execution. The handoffs became the weakness.
The Most Expensive Word May Be “Approved”
There is something psychologically powerful about approval. Approval feels like completion. It gives organizations a clear milestone. The committee voted. Leadership agreed. The contract was signed. The project can move forward. But operationally, approval is closer to the starting line than the finish line.
The economic value of a standardization initiative does not occur when the committee approves the preferred product. It occurs when purchases actually shift. The value of a utilization initiative does not occur when clinicians agree with the recommendation. It occurs when practice changes. The value of a new technology does not occur when capital is approved. It occurs when appropriate utilization produces the clinical, operational, or financial results included in the business case. The value of a contract does not occur when signatures are complete. It occurs when the organization buys according to it.
Those distinctions sound simple. In practice, this changes how organizations should govern Value Analysis.
Projected Savings Are Not the Same as Realized Value
These distinctions become especially important when organizations are under significant financial pressure. Healthcare leaders are increasingly asking Supply Chain and Value Analysis teams to demonstrate measurable financial impact. That makes the difference between projected savings and realized value critically important.
Suppose an organization standardizes a product category and calculates a $1 million annual opportunity. The analysis may be correct, but if only 70 percent of volume converts, the financial result will look very different.
If physicians continue using exceptions, the result changes again. If the organization continues purchasing old inventory at certain sites, the result changes. If procedure volumes decline, the original calculation may no longer hold. If pricing is loaded incorrectly, the expected savings may never appear. If a more expensive alternative begins gaining utilization elsewhere in the category, the savings may be offset entirely.
None of this necessarily means the sourcing strategy failed. It means the organization needs visibility beyond the original decision. A savings estimate tells us what could happen. Value realization tells us what did happen. Mature organizations need both.
Implementation Should Be Designed Before Approval
One of the simplest ways to improve value realization is to stop treating implementation as something that begins after approval. Implementation planning should be part of the decision itself. Before an initiative receives final approval, the organization should understand several things:
- Who owns implementation?
- What departments and locations are affected?
- What inventory must be depleted?
- What operational systems need to change?
- What education is required?
- What supplier support is necessary?
- When will conversion occur?
- What exceptions will be permitted?
- How will compliance be measured?
- What outcome is expected?
- Who will review performance after implementation?
And perhaps most importantly: What would cause this initiative to fail after we approve it?
That last question can expose risks that a traditional product evaluation may never identify. A clinically acceptable product with an attractive financial opportunity can still be a poor organizational decision if the implementation requirements are unrealistic. Conversely, understanding those barriers before approval allows the organization to build a realistic implementation strategy rather than discovering problems during conversion.
Value Analysis Cannot Do This Alone
Expanding the focus from approval to value realization does not mean Value Analysis should personally execute every task after a decision. That would create another problem entirely. Value Analysis should not become the project manager, analyst, contracting team, educator, inventory manager, clinician liaison, and compliance department for every initiative.
Instead, Value Analysis can help establish the governance that connects those functions. That means clearly defining ownership across Supply Chain, Strategic Sourcing, Procurement, Decision Support and Analytics, Finance, Clinical Operations, suppliers, and other stakeholders.
Different initiatives will require different levels of rigor. A minor product substitution should not require the same implementation infrastructure as a major physician-preference conversion or enterprise technology investment. But the principle remains the same: Someone must own the outcome, and the organization must know who that is.
Measure What Happened, Not Just What Was Decided
This is another area where Value Analysis programs can evolve. Many organizations have excellent records of what their committees approved. Far fewer can easily demonstrate what happened afterward.
Imagine if every major Value Analysis initiative returned for a structured post-implementation review. Not another meeting for the sake of having another meeting. A short, disciplined review of the original business case against actual performance.
- What did we expect?
- What happened?
- Did utilization change as planned?
- Did we achieve the expected compliance?
- Did the financial result materialize?
- Were there unintended clinical or operational consequences?
- Did exceptions emerge?
- Did the implementation create additional workload?
- Should the initiative continue as designed, be adjusted, or be reconsidered?
That feedback loop does more than validate one project. It improves the quality of future decisions. Organizations begin learning which assumptions are reliable, which implementation strategies work, where adoption typically breaks down, and which types of initiatives require greater support. Value Analysis then becomes not simply a decision-making function, but an organizational learning system. That is a much more powerful role.
Suppliers Have a Role in Value Realization Too
Suppliers should pay attention to this evolution. Winning approval is not the same as winning sustainable business. A supplier can successfully navigate Value Analysis, receive contract access, and still fail to achieve meaningful adoption. The suppliers that understand this recognize that their responsibility does not end with the sale.
They need to understand implementation, clinical workflow, contracting and purchasing behavior, and how hospitals measure utilization and compliance. They need to anticipate operational barriers. And they need to demonstrate value after implementation, not simply present projected value before it.
This changes the provider-supplier conversation. Instead of asking only, “How do we get approved?”, the better question becomes, “How do we help the organization successfully achieve the outcome we promised?” That is a much stronger foundation for partnership!
The Next Evolution of Value Analysis
Value Analysis has already evolved considerably. What began in many organizations primarily as product review has increasingly become a sophisticated intersection of clinical evidence, financial stewardship, supply chain strategy, operational performance, and patient care.
The next evolution is to connect those capabilities more deliberately to execution. That means moving from:
- Approval to adoption.
- Projected savings to realized value.
- Committee ownership to enterprise accountability.
- Product evaluation to lifecycle management.
- Individual decisions to measurable organizational outcomes.
This does not diminish the importance of rigorous evaluation, it completes it. Because the best product evaluation in the world has limited value if the organization cannot successfully implement the decision. The strongest contract delivers little if purchasing behavior never changes. The most compelling business case means very little if nobody returns later to determine whether its assumptions were correct. And an approval that never becomes operational reality is ultimately just an approval.
The Finish Line Has Moved
Healthcare organizations cannot afford to measure success by how much activity occurs inside their Value Analysis programs. The number of requests reviewed is not the outcome. The number of meetings held is not the outcome. The number of initiatives approved is not the outcome. Even the amount of projected savings is not the final outcome. The outcome is what changed because the organization made the decision.
- Did patient care improve?
- Did clinical workflow improve?
- Did unnecessary variation decrease?
- Did utilization become more appropriate?
- Did operational performance improve?
- Did financial value actually materialize?
- Did the change sustain?
Those are harder questions. They are also the questions that matter. The next generation of Value Analysis will not be defined solely by how rigorously healthcare organizations make decisions.
It will be defined by how reliably those decisions become results, because approval is an important milestone. But value isn’t created when the committee votes. Value is created when the organization changes what happens afterward.
Article by:
Angelique Weiley Beslic, CHSCM, Founder, The Bridge Venturers, LLC
Angelique Weiley Beslic is a healthcare supply chain executive, educator, consultant, and founder of The Bridge Venturers, LLC and the Healthcare Supply Chain Hub. With nearly three decades of experience across healthcare providers, suppliers, distributors, and manufacturers, her work focuses on clinically integrated supply chain, strategic sourcing and contracting, value analysis, analytics, procurement, governance, and healthcare supply chain transformation.
Angelique is the developer of an ISCEA-accredited healthcare supply chain education and certification portfolio, including the Certification in Healthcare Supply Chain Foundations and the Certified Healthcare Supply Chain Manager (CHSCM) pathway. Through The Bridge Venturers and the Healthcare Supply Chain Hub, she works to strengthen healthcare supply chain capability across both provider and supplier organizations and help professionals better understand how decisions move from strategy to execution and measurable value.
Articles you may like:
Supplier Fragmentation Is Quietly Destroying Healthcare Operations
